<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523224</url>
  </required_header>
  <id_info>
    <org_study_id>TV-002</org_study_id>
    <secondary_id>ACPs-CHF</secondary_id>
    <nct_id>NCT00523224</nct_id>
  </id_info>
  <brief_title>ACPs Combined With CABG in Patients With CHF</brief_title>
  <official_title>A Study of Combined Coronary Artery Bypass Grafting (CABG) and Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Congestive Heart Failure Due to Ischemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TheraVitae Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TheraVitae Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study title: A Study of Combined Coronary Artery Bypass Grafting (CABG) and Blood-Borne&#xD;
      Autologous Angiogenic Cell Precursors Therapy in Patients with Congestive Heart Failure due&#xD;
      to Ischemic Heart Disease (ACPs-CHF) Principle Investigator: Kit V. Arom ,M.D.,Ph.D. Deputy&#xD;
      Director, Chief Cardio-Thoracic Surgeon, Bangkok Heart Hospital Study objective : To&#xD;
      determine the safety and efficacy of injection of blood-borne autologous ACPs into the&#xD;
      non-graftable area of the heart of patients with congestive heart failure due to ischemic&#xD;
      heart disease Its main goal is evaluation of feasibility and safety of the combined&#xD;
      technique. The efficacy of the treatment will be tested in the following trial.&#xD;
&#xD;
      Study Design : Phase I , a single center, a non-randomized, open-label trial to test the&#xD;
      safety, of intramyocardium transepicardium administration of ex vivo expanded autologous ACPs&#xD;
      administered in combination with CABG operation in patients with congestive heart failure due&#xD;
      to ischemic heart disease.&#xD;
&#xD;
      The study is a preliminary training study, under the supervision of the experienced Dr. Patel&#xD;
      the U.S. principal investigator.&#xD;
&#xD;
      Study population :&#xD;
&#xD;
      Total expected no. of patients : 5 main selection criteria :&#xD;
&#xD;
        1. Patients with or without signs of congestive heart failure due to ischemic heart disease&#xD;
           who had maximal medical treatments. Not suitable to percutaneous intervention&#xD;
&#xD;
        2. All patients must have a recent coronary angiogram. Patients must be able to have OPCAB&#xD;
           and then have Angiogenic Cell Precursors(ACPs) in non-graftable and/or infraction&#xD;
           regions&#xD;
&#xD;
        3. Age 18 to 80 years&#xD;
&#xD;
        4. MRI demonstrating areas of viable and non-viable myocardium Investigational Product :&#xD;
           The patients will be blood drawn 250 ml at D-8 for producting autologous ACPs&#xD;
           (VescellTM), On D0 ,at least 1.5 million ACPs with viability &gt;75 % supended in 15 ml&#xD;
           sterile cell culture medium will be injected 1 cm apart using a 23 gauge angled needle&#xD;
           in 30 spots (0.5 ml /point) to the same patients by direct intramuscular approach at LV&#xD;
           during CABG.&#xD;
&#xD;
      The study consists of 4 periods: Screening ( D-14 to-9&amp; D-8,Treatment(D0),Acute Safety&#xD;
      follow-up (D1-2&amp; D5-discharge),Chronic follow-up (D30 &amp; D90)period ,total follow-up of each&#xD;
      case is 3 months.&#xD;
&#xD;
      Evaluation criteria :&#xD;
&#xD;
      Safety : no.&amp; duration of adverse event &amp; serious adverse event Efficacy :NYHA, 6-minute&#xD;
      walking test ,% LVEF by Echocardiography &amp; C-MRI, % infracted scar area on C-MRI , Pro-BNP &amp;&#xD;
      3 months of QoL(SF-36)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Five CAD patients who required CABG with or without congestive heart failure will undergo&#xD;
      screening and receiving of ACPs 's injection by direct intramuscular during CABG operation.&#xD;
      After that,the patients will come to follow up with investigator at 1 and 3 months post&#xD;
      surgery in order to evaluate safety and efficacy of stem cells therapy(ACPs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">September 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation criteria</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety : no.&amp; duration of adverse event &amp; serious adverse event</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy : EF , NYHA</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline to 1 &amp; 3 months of NYHA, 6-minute walking test</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to 3 months of QoL(SF-36)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy:%EF,NYHA</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline to 3 months of % LVEF by Echocardiography &amp; C-MRI</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline to 3 months of % infracted scar area on C-MRI</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline to 3 months of QoL(SF-36)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open lable,single arm , intervention is Angiogenic Cell Precusors(ACPs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiogenic Cell Precursors(ACPs) or Vescell TM</intervention_name>
    <description>at least 1.5 million of ACPs per one time of treatment</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Angiogenic Cell Precusors</intervention_name>
    <description>Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with or without signs of congestive heart failure due to ischemic heart&#xD;
             disease who had maximal medical treatments. Not suitable to percutaneous intervention&#xD;
&#xD;
          2. All patients must have a recent coronary angiogram. Patients must be able to have&#xD;
             OPCAB and then have Angiogenic Cell Precursors(ACPs) in non-graftable and/or&#xD;
             infraction regions&#xD;
&#xD;
          3. Age 18 to 80 years&#xD;
&#xD;
          4. Male or non-pregnant, non-lactating female&#xD;
&#xD;
          5. MRI demonstrating areas of viable and non-viable myocardium&#xD;
&#xD;
          6. Informed consent obtained and consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior Cardiac Surgery or Heart Transplantation&#xD;
&#xD;
          2. Patient who received blood transfusions during the previous 4 weeks (to exclude the&#xD;
             potential of non-autologous ACPs in the harvested blood).&#xD;
&#xD;
          3. Inability to communicate (that may interfere with the clinical evaluation of the&#xD;
             patient)&#xD;
&#xD;
          4. Acute Myocardial infarction &lt; 6 days from acute event&#xD;
&#xD;
          5. Significant valvular disease or after valve replacement&#xD;
&#xD;
          6. Left Ventricular Aneurysm&#xD;
&#xD;
          7. Collagen tissue disease&#xD;
&#xD;
          8. History of Prior Radiation Exposure&#xD;
&#xD;
          9. History of alcohol or drug abuse within 3 months of screening&#xD;
&#xD;
         10. Renal failure (creatinine &gt; 2 mg/dl) or Hemodialysis&#xD;
&#xD;
         11. Hepatic failure or History of Liver Cirrhosis&#xD;
&#xD;
         12. Females who are capable of reproduction and will not take acceptable measures to&#xD;
             prevent reproduction during the study.&#xD;
&#xD;
         13. Anemia (lower than 11mg/dl.hemoglobin for female and lower than 12 mg/dl for male)&#xD;
&#xD;
         14. Abnormal coagulation tests normal [platelets, PT (INR), PTT]&#xD;
&#xD;
         15. Stroke within the preceding 3 years&#xD;
&#xD;
         16. Malignancy within the preceding 3 years&#xD;
&#xD;
         17. Concurrent chronic or acute infectious disease&#xD;
&#xD;
         18. Severe concurrent medical disease (e.g., septicemia, HIV-1,2/HBV/HCV infections,&#xD;
             insulin-dependent diabetes mellitus, systemic lupus erythematosus, multiple sclerosis,&#xD;
             amyotrophic lateral sclerosis)&#xD;
&#xD;
         19. Chronic immunomodulating or cytotoxic drugs treatment&#xD;
&#xD;
         20. Patients who have rectal temp. above 38.40C for 2 consecutive days&#xD;
&#xD;
         21. Patient unlikely to be available for follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kitipan Visudharom, Ph.D.,M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangkok Heart Hospital, 2 Soi Soonvijai 7,New Petchburi Rd.,Bangkok 10310 Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wannapa Kulwathanaporn, Master</last_name>
    <phone>++66-2-664-4290</phone>
    <phone_ext>141</phone_ext>
    <email>wannapa@theravitae.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Czeiger, Ph.D.,M.D.</last_name>
    <phone>+972 54-208-0405</phone>
    <email>dudyc@theravitae.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Theravitae Co.</name>
      <address>
        <city>Tel viv</city>
        <state>P.O. B 4049,Ness Ziona</state>
        <zip>74410</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Belkin, Ph.D.</last_name>
      <phone>+972-8-9409170</phone>
      <email>dbelkin@theravitae.com</email>
    </contact>
    <contact_backup>
      <last_name>Michael Belkin, Ph.D.,M.D.</last_name>
      <phone>+972-3-530-2956</phone>
      <email>belkin@netvision.net.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>August 30, 2007</study_first_submitted>
  <study_first_submitted_qc>August 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <last_update_submitted>August 30, 2007</last_update_submitted>
  <last_update_submitted_qc>August 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2007</last_update_posted>
  <keyword>Stem cells</keyword>
  <keyword>Coronary Artery Bypass grafting</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Angiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

